Business context and reporting period
Replimune Group, Inc. is a clinical-stage biotechnology company developing tumor-directed oncolytic immunotherapies, including RP1, RP2 and RP3. It has no approved products and has generated no product-sales revenue. This unaudited Form 10-Q covers the quarter and nine months ended December 31, 2022; the company’s fiscal year ends March 31.
Financial results and liquidity
Amounts below are in millions of dollars unless otherwise noted.
| Metric | Quarter ended Dec. 31, 2022 | Prior-year quarter | Nine months ended Dec. 31, 2022 | Prior-year nine months |
|---|---|---|---|---|
| Research and development expense | $30.3 | $19.4 | $88.6 | $57.8 |
| Selling, general and administrative expense | $11.4 | $10.3 | $35.5 | $28.5 |
| Net loss | $39.7 | $29.7 | $125.0 | $86.3 |
| Net loss per share, basic and diluted | $0.69 | $0.57 | $2.25 | $1.66 |
- Cash and investments: $616.4 at December 31, 2022, comprising $206.7 cash and cash equivalents and $409.7 short-term investments. The company also reported $1.6 restricted cash.
- Cash flows, nine months: $95.3 used in operating activities; $119.8 used in investing activities, primarily reflecting net purchases of short-term investments; and $311.4 provided by financing activities. Ending cash, cash equivalents and restricted cash were $208.3.
- Debt and leases: Long-term debt was $28.4 net of discount and costs, following an initial $30.0 draw under a Hercules term-loan facility. Finance-lease liabilities were $26.7; operating-lease liabilities were $5.3. The facility permits additional borrowing subject to options, milestones and other conditions.
- Balance sheet: Total assets were $678.6 and stockholders’ equity was $595.3. Accumulated deficit was $436.2. No gross margin or product revenue is reported because there are no product sales.
Material changes and operating developments
- Quarterly operating expenses increased $11.9 year over year; nine-month expenses rose $37.8. R&D growth reflected clinical-trial activity, staffing and manufacturing process development and validation. SG&A growth included additional personnel and pre-commercial planning.
- Quarterly net loss increased $10.0 year over year; nine-month net loss increased $38.7. Higher investment income partly offset expense growth, while nine-month other expense also reflected foreign-exchange movements and new debt interest.
- In December 2022, the company completed a public offering, reporting approximately $242.6 net proceeds from common stock and pre-funded warrants. Common shares issued and outstanding rose to 56.6 million from 47.3 million at March 31, 2022; 9.5 million shares underlying pre-funded warrants were not included in the balance-sheet share count.
- Regeneron’s cost sharing for the original CERPASS study budget ended in June 2022; the company does not expect further reimbursements under that plan.
Outlook, commentary and risks
- Management reported cash and investments sufficient to fund operations into the second half of 2025, including commercial infrastructure and a confirmatory melanoma trial, and referenced available Hercules borrowing. However, the risk-factor discussion separately estimated funding into the second half of calendar 2024, excluding a confirmatory trial. These differing runway statements should be reconciled; both depend on assumptions and are not guarantees.
- The company expects continued, increasing operating losses and says it will need substantial funding to meet its objectives. Additional financing may dilute shareholders or impose restrictive terms; collaboration or licensing could require giving up rights.
- CERPASS topline data was expected in Q3 2023 after the company chose a primary analysis at 40 weeks after last patient in, rather than the minimum 27 weeks. In February 2023, after the reporting quarter, the FDA responded to the draft statistical analysis plan with points and recommendations requiring further discussion.
- For IGNYTE, December 2022 data from the first 75 anti-PD-1-failed melanoma patients with at least six months’ follow-up showed investigator-assessed 20% complete response and 36% overall response rates. The company expected enrollment to finish in February 2023 and primary analysis in Q1 2024. These are clinical updates, not financial results or regulatory determinations.
- Management planned to initiate RP2/RP3 Phase 2 signal-finding studies around mid-2023. Key risks include clinical efficacy and safety, FDA requirements and timing, manufacturing validation and supply, reliance on collaborators and third parties, competition, future financing needs, COVID-related disruption and foreign-exchange volatility.
- The company disclosed an inter partes review petition filed in November 2022 challenging certain claims of an Amgen patent. It reported no material legal proceedings or litigation contingency reserve.
Important facts for investors to verify
- Reconcile the stated cash-runway estimates—second half of 2025 versus second half of 2024—and confirm which spending and trial assumptions each includes.
- Track FDA discussions on the CERPASS statistical analysis plan, the revised analysis timing and whether results support any regulatory filing.
- Review clinical-trial updates against final, centrally reviewed data and regulatory feedback; early response rates do not establish approval or commercial benefit.
- Assess operating cash burn, planned trial and manufacturing spending, available—not merely maximum—Hercules borrowing, and the potential for further equity dilution.
- Monitor in-house manufacturing validation, supply continuity and the status and potential consequences of the patent review.